Abstract Library

#1551 Establishment and Characterization of Three GEP-NEC Cell Lines for In Vitro and In Vivo Studies

Introduction: To date chemotherapeutic concepts applying cisplatin/etoposide for the treatment of highly aggressive GEP-NEC do not provide convincing results. Thus, there is an urgent need for NEC cell line models that provide a reliable experimental system in identifying novel therapeutic targets.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Krieg A

Authors: Krieg A, Riemer J, Dizdar L, Mersch S, Anlauf M,

Keywords: GEP-NEC,

#1102 First-Line Chemotherapy in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): A Retrospective Analysis

Introduction: Gastroenteropancreatic neuroendocrine neoplasia (GEP-NENs) are divided on the basis of Ki67 status into G1-G2 neuroendocrine tumors (NETs) (Ki67 <20%) and neuroendocrine carcinoma (NECs) (Ki67 >20% ). NEC patients generally have a poor prognosis and the first choice treatment is chemotherapy.A cisplatin/etoposide combination is often used as NECs are considered clinically similar to small cell lung cancer (SCLC), but no literature data is available. There is some evidence to suggest that carboplatin may also be effective in metastatic SCLC.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: IBRAHIM T

Authors: Bongiovanni A, Riva N, Monti M, Ianniello A, Pieri F,

Keywords: GEP-NEC,chemotherapy,

#916 PET+10 Study: Efficacy of Platin/Etoposide Combination in Well-Differentiated Pancreatic Neuroendocrine Tumors with Ki-67 ≥ 10%

Introduction: Platin-etoposide (PE), the gold standard regimen for poorly differentiated neuroendocrine carcinomas, might be effective in well-differentiated pancreatic neuroendocrine tumors (WD-PNETs) with a high Ki-67 proliferation index.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: BAUDIN E

Authors: Roquin G, Baudin E, Lombard-Bohas C, Cadiot G, Dominguez S,

Keywords: platin/etoposide, pNETs, Ki-67,

#714 Oxalipatin-Based Chemotherapy for Grade 3 Neuroendocrine Carcinoma after Failure of Platinum- Based Chemotherapy

Introduction: Cisplatin/etoposide regimen is the recommended first line treatment for poorly differentiated grade 3 neuroendocrine carcinoma (G3-NEC). There is no standard second line.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Hadoux J, Guigay J, Malka D, Planchard D, Boige V,

Keywords: neuroendocrine carcinoma, grade 3, oxaliplatin,

#602 Antitumoral Effect of Everolimus in Preclinical Models of Poorly Differentiated Neuroendocrine Carcinomas

Introduction: For the small and large cells poorly differentiated neuroendocrine carcinomas (PDNECs) emergency treatment remains the combination cisplatin/etoposide. However, recent studies suggest that targeted therapies could be a therapeutic option for this group of highly aggressive carcinomas.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Bollard J, Couderc C, Blanc M, Poncet G, Lepinasse F,

Keywords: everolimus, poorly differentiated neuroendocrine carcinoma, preclinical study,